Antifungal agents for common paediatric infections;Les antifongiques dans le traitement des infections pédiatriques courantes

Paediatrics and Child Health

Volumn 12, Issue 10, 2007, Pages 875-883

  Bortolussi, Robert ^a   Moore, Dorothy L ^b   Robinson, Joan Louise ^c   Rousseau Harsany, Élisabeth ^d   Samson, Lindy Michelle ^e   MacDonald, Noni E ^a   Allen, Upton Dilworth ^f   Halperin, Scott Alan ^a   Hui, Charles P S ^e   Pickering, Larry ^c   Salvadori, Marina Ines ^g  

^a IWK HEALTH CENTRE   (Canada)

^b MONTREAL CHILDREN S HOSPITAL   (Canada)

^c Sainte Justine UHC ^*

^d UNIVERSITY OF MONTREAL   (Canada)

^e CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^f HOSPITAL FOR SICK CHILDREN   (Canada)

^g CHILDREN S HOSPITAL OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM ACETATE SOLUTION; ANTIARRHYTHMIC AGENT; ANTIFUNGAL AGENT; ANTIINFLAMMATORY AGENT; CANDISTATIN; CLOTRIMAZOLE; CRYSTAL VIOLET; CYCLOSPORIN; ESTRADIOL; FLUCONAZOLE; GRISEOFULVIN; HYDROCORTISONE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; MICOZOLE; NYSTATIN; PLACEBO; PYRROLE DERIVATIVE; SELENIUM SULFIDE; TACROLIMUS; TERBINAFINE; UNCLASSIFIED DRUG; ZINC OXIDE;

CANDIDA ALBICANS; CLINICAL TRIAL; DIAPER DERMATITIS; DOSE RESPONSE; DRUG EFFICACY; DRUG METABOLISM; GASTROINTESTINAL SYMPTOM; HUMAN; MUCOCUTANEOUS CANDIDIASIS; MYCOSIS; ONYCHOMYCOSIS; REVIEW; SEBORRHEIC DERMATITIS; SKIN MANIFESTATION; TASTE DISORDER; THRUSH; TINEA CAPITIS; TINEA CORPORIS; TINEA CRURIS; TINEA PEDIS; TINEA VERSICOLOR; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 39649119850     PISSN: 12057088     EISSN: None     Source Type: Journal    
DOI: 10.1093/pch/12.10.875     Document Type: Review

References (51)

1. Gupta AK, Cooper EA, Ryder JE, Nicol KA, Chow M, Chaudhry MM. Optimal management of fungal infections of the skin, hair, and nails. Am J Clin Dermatol 2004;5:225-37.
2. Canadian Paediatric Society, Infectious Diseases and Immunization Committee [Principal Author: S King]. Antifungal agents for common paediatric infections. Paediatr Child Health 2000;5:477-82.
3. Linder N, Levit O, Klinger G, et al. Risk factors associated with candidaemia in the neonatal intensive care unit: A case-control study. J Hosp Infect 2004;57:321-4.
4. Yamamura DL, Rotstein C, Nicolle LE, Ioannou S. Candidemia at selected Canadian sites: Results from the Fungal Disease Registry, 1992-1994. CMAJ 1999;160: 493-9.
5. Clarkson JE, Worthington HV, Eden OB. Interventions for treating oral candidiasis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2004;(1):CD001972.
6. Butler KM, Baker CJ. Candida: An increasingly important pathogen in the nursery. Pediatr Clin North Am 1988;35:543-63.
7. Baley JE, Kliegman RM, Boxerbaum B, Fanaroff AA. Fungal colonization in the very low birth weight infant. Pediatrics 1986;78:225-32.
8. Sio JO, Minwalla FK, George RH, Booth IW. Oral Candida: Is dummy carriage the culprit? Arch Dis Child 1987;62:406-8.
9. Faber HK, Dickey LB. The treatment of thrush with gentian violet. JAMA 1925;85:900-1.
10. Huang NN, Sarria A, High RH. Therapeutic evaluation of nystatin and amphotericin in oral moniliasis in infants and children. Antibiot Annu 1957-1958;5:59-64.
11. Boon JM, Lafeber HN, Mannetje AH, et al. Comparison of ketoconazole suspension and nystatin in the treatment of newborns and infants with oral candidiasis. Mycoses 1989;32:312-5.
12. Hoppe JE. Treatment of oropharyngeal candidiasis in immunocompetent infants: A randomized multicenter study of miconazole gel versus nystatin suspension. The Antifungals Study Group. Pediatr Infect Dis J 1997;16:288-93.
13. Kirkpatrick CH, Alling DW. Treatment of chronic oral candidiasis with clotrimazole troches. A controlled clinical trial. N Engl J Med 1978;299:1201-3.
14. Mansour A, Gelfand EW. A new approach to the use of antifungal agents in children with persistent oral candidiasis. J Pediatr 1981;98:161-2.
15. Grossman ER. Treatment of thrush. Pediatr Infect Dis J 1988;7:303.
16. Rebora A, Leyden JJ. Napkin (diaper) dermatitis and gastrointestinal carriage of Candida albicans. Br J Dermatol 1981;105:551-5.
17. Concannon P, Gisoldi E, Phillips S, Grossman R. Diaper dermatitis: A therapeutic dilemma. Results of a double-blind placebo controlled trial of miconazole nitrate 0.25%. Pediatr Dermatol 2001;18:149-55.
18. Dixon PN, Warin RP, English MP. Alimentary Candida albicans and napkin rashes. Br J Dermatol 1972;86:458-62.
19. Munz D, Powell KR, Pai CH. Treatment of candidal diaper dermatitis: A double-blind placebo-controlled comparison of topical nystatin with topical plus oral nystatin. J Pediatr 1982;101:1022-5.
20. Schwartz RA. Superficial fungal infections. Lancet 2004;364:1173-82.
21. Gupta AK, Batra R, Bluhm R, Faergemann J. Pityriasis versicolor. Dermatol Clin 2003;3:413-29.
22. Ginsberg CM. Malassezia species. In: Long SS, Pickering LK, Prober CG, eds. Principles and Practice of Pediatric Infectious Diseases. New York: Churchill Livingston, 1997:1337-8.
23. Mellen LA, Vallee J, Feldman SR, Fleischer AB Jr. Treatment of pityriasis versicolor in the United States. J Dermatolog Treat 2004;15:189-92.
24. Gupta AK, Einarson TR, Summerbell RC, Shear NH. An overview of topical antifungal therapy in dermatomycoses. A North American perspective. Drugs 1998;55:645-74.
25. Lange DS, Richards HM, Guarnieri J, et al. Ketoconazole 2% shampoo in the treatment of tinea versicolor: A multicenter, randomized, double-blind, placebo controlled trial. J Am Acad Dermatol 1998;39:944-50.
26. Ginsberg CM. Dermatophytes and other superficial fungi. In: Long SS, Pickering LK, Prober CG, eds. Principles and Practice of Pediatric Infectious Diseases. New York: Churchill Livingston, 1997:1359-62.
27. Gupta AK, Sibbald RG, Lynde CW, et al. Onychomycosis in children: Prevalence and treatment strategies. J Am Acad Dermatol 1997;36:395-402.
28. Bräutigam M. Terbinafine versus itraconazole: A controlled clinical comparison in onychomycosis of toenails. J Am Acad Dermatol 1998;38:S53-6.
29. De Backer M, De Vroey C, Lesaffre E, Scheys I, De Keyser P. Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: A double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. J Am Acad Dermatol 1998;38:S57-63.
30. Grant SM, Clissold SP. Fluconazole: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 1990;39:877-916. (Erratum in 1990;40:862).
31. Gatti S, Marinaro C, Bianchi L, Nini G. Treatment of kerion with fluconazole. Lancet 1991;338:1156.
32. Solomon BA, Collins R, Sharma R, et al. Fluconazole for the treatment of tinea capitis in children. J Am Acad Dermatol 1997;37:274-5.
33. López-Gómez S, Del Palacio A, Van Cutsem J, Soledad Cuétara M, Iglesias L, Rodriguez-Noriega A. Itraconazole versus griseofulvin in the treatment of tinea capitis: A double-blind randomized study in children. Int J Dermatol 1994;33:743-7.
34. Legendre R, Esola-Macre J. Itraconazole in the treatment of tinea capitis. J Am Acad Dermatol 1990;23:559-60.
35. Lukacs A, Korting HC, Lindner A. Successful treatment of griseofulvin-resistant tinea capitis in infants. Mycoses 1994;37:451-3.
36. Elewski BE. Tinea capitis: Itraconazole in Trichophyton tonsurans infection. J Am Acad Dermatol 1994;31:65-7.
37. Greer DL. Treatment of tinea capitis with itraconazole. J Am Acad Dermatol 1996;35:637-8.
38. Tanz RR, Stagl S, Esterly NB. Comparison of ketoconazole and griseofulvin for the treatment of tinea capitis in childhood: A preliminary study. Pediatr Emerg Care 1985;1:16-8.
39. Tanz RR, Hebert AA, Esterly NB. Treating tinea capitis: Should ketoconazole replace griseofulvin? J Pediatr 1988;112:987-91.
40. Gan VN, Petruska M, Ginsburg CM. Epidemiology and treatment of tinea capitis: Ketoconazole vs griseofulvin. Pediatr Infect Dis J 1987;6:46-9.
41. Martinez-Roig A, Torres-Rodriguez JM, Bartlett-Coma A. Double-blind study of ketoconazole and griseofulvin in dermatophytoses. Pediatr Infect Dis J 198;7:37-40.
42. Faergemann J, Zehender H, Denouël J, Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks. Acta Derm Venerol 1993;73:305-9.
43. McClellan KJ, Wiseman LR, Markham A. Terbinafine. An update of its use in superficial mycoses. Drugs 1999;58:179-202.
44. Haroon TS, Hussain I, Mahmood A, Nagi AH, Ahmad I, Zahid M. An open clinical pilot study of the efficacy and safety of oral terbinafine in dry non-inflammatory tinea capitis. Br J Dermatol 1992;126(Suppl39):47-50.
45. Nejjam F, Zagula M, Cabiac MD, Guessous N, Humbert H, Lakhdar H. Pilot study of terbinafine in children suffering from tinea capitis: Evaluation of efficacy, safety and pharmacokinetics. Br J Dermatol 1995;132:98-105.
46. Alvi KH, Iqbal N, Khan KA, et al. A randomized double-blind trial of the efficacy and tolerability of terbinafine once daily compared to griseofulvin once daily in treatment of tinea capitis. In: Shuster S, Jafary MH, eds. Royal Society of Medicine Services International Congress Series, no 205. London: Royal Society of Medicine Press Ltd, 1992:35-40.
47. Haroon TS, Hussain I, Aman S, et al. A randomized double-blind comparative study of terbinafine for 1, 2 and 4 weeks in tinea capitis. Br J Dermatol 1996;135:86-8.
48. Kullavanijaya P, Reangchainam S, Ungpakorn R. Randomized single-blind study of efficacy and tolerability of terbinafine in the treatment of tinea capitis. J Am Acad Dermatol 1997;37:272-3.
49. Gupta AK, Cooper EA, Lynde CW. The efficacy and safety of terbinafine in children. Dermatol Clin 2003;21:511-20.
50. Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf 1998;18:83-97.
51. Howard RM, Frieden HJ. Dermatophyte infections in children. In: Aronoff SC, Hughes WT, Kohl HS, Prince A, eds. Advances in Pediatric Infectious Diseases, Vol 14. St Louis: Mosby-Year Book, 1999:73-108.